Journals / Retina-Vitreus / 2012 / Cilt: 20 - Sayı: 1

Our results of follow up and treatment in retinopathy of prematurity

Prematüre retinopatisinde takip ve tedavi sonuçlarımız

Pages
45–49
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Adjuvant treatment with IVB is very effective and promising, especially in eyes with hazy media and/or refractory to the ALP treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To determine the frequency of retinopathy of prematurity (ROP) and the results of the treatment with argon laser photocoagulation (ALP) and intravitreal bevacizumab (IVB) injection.
📊
Key Findings & Data:Material and Methods: The records of the premature babies were retrospectively evaluated between June 2010 and May 2011.
💡
Conclusion & Impact:Adjuvant treatment with IVB is very effective and promising, especially in eyes with hazy media and/or refractory to the ALP treatment.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To determine the frequency of retinopathy of prematurity (ROP) and the results of the treatment with argon laser photocoagulation (ALP) and intravitreal bevacizumab (IVB) injection. Material and Methods: The records of the premature babies were retrospectively evaluated between June 2010 and May 2011. Birth weight, gestational age, retinopathy grade and zone were investigated. Indirect ALP ± IVB were performed when prethreshold ROP was detected. Results: The records of 285 premature babies were evaluated. Of them, 150 were male, and 135 were female. Mean gestational age was 29.9±3.1 weeks and mean birth weight was 1443±518 g. ROP was detected in 180 patients. Sixty eyes of 30 patients were treated with ALP. Eight eyes of 5 patients were treated with adjuvant IVB. In patients with lower gestational age and lower birth weight, the stage of the ROP was more advanced (p<0.001). ROP was regressed in 28 of 30 patients after treatment. Retinal detachment developed in 2 eyes of 2 patients, who had previously diagnosed as threshold disease. Conclusion: the results of ALP treatment at the prethreshold disease were successful, and the complications were lower. Adjuvant treatment with IVB is very effective and promising, especially in eyes with hazy media and/or refractory to the ALP treatment.

Özet

Amaç: Prematüre retinopatisi (PR) sıklığını tanımlamak ve argon lazer fotokoagulasyon (ALF) ve intravitreal bevacizumab (İVB) enjeksiyonu ile tedavi sonuçlarını bildirmek. Gereç ve Yöntem: Haziran 2010 ile Mayıs 2011 tarihleri arasında muayene edilen prematüre bebeklere ait kayıtlar geriye dönük olarak incelendi. Doğum ağırlığı, gestasyonel yaş, retinopati evresi ve zonu araştırıldı. Eşik öncesi hastalık saptanan bebeklere indirek ALF±İVB tedavisi uygulandı. Bulgular: İkiyüzseksenbeş prematüre bebeğe ait kayıtlar incelendi. Ortalama gestasyonel yaş 29,9±3,1 hafta ve ortalama doğum ağırlığı 1443±518 gram idi. Prematüre retinopati 180 olguda saptandı. Otuz hastanın 60 gözü ALF ile tedavi edildi. Beş hastanın sekiz gözü ek İVB ile tedavi edildi. Düşük doğum ağırlığı ve düşük doğum haftası olan bebeklerde PR evresi daha ileri saptandı (p<0.001). 30 hastanın 28’inde tedavi sonrasında PR geriledi. Önceden eşik hastalık tanısı konan 2 hastanın 2 gözünde ise retina dekolmanı gelişti. Sonuç: Eşik öncesi hastalıkta ALF tedavisi sonuçları başarılı ve komplikasyonlar daha düşüktür. İVB ile adjuvan tedavi, özellikle ortam bulanıklığı olan gözlerde ve ALF tedavisine yanıtın düşük olduğu gözlerde oldukça etkili ve ümit vaat edici gözükmektedir.

🔖

Cite This Article

ŞAHİN, A., ARI, Ş., CİNGÜ, A. K., PEKER, Ü., KARAOĞLU, M. M., YOLBAŞ, İ., ÇAÇA, İ. (2012). Our results of follow up and treatment in retinopathy of prematurity. Retina-Vitreus, Cilt: 20 - Sayı: 1, 45–49. https://ajindex.com/articles/307684

References (15)

  1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am J Ophthalmol 1942;25:203-4
  2. Roohipoor R, Ghasemi H, Ghassemi F, et al. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Graefes Arch Clin Exp Ophthalmol 2011;249:1295-301
  3. Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15
  4. Harder BC, Baltz SV, Jonas JB, et al. Intravitreal Bevacizumab for Retinopathy of Prematurity. J Ocul Pharmacol Ther 2011 Aug 8. [Epub ahead of print] doi:10.1089/jop.2011.0060
  5. Nazari H, Modarres M, Parvaresh MM, et al. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 2010;248:1713-8
  6. Early Treatment For Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94
  7. Ng YK, Fielder AR, Shaw DE, et al. Epidemiology of retinopathy of prematurity. Lancet 1988;2:1235-8
  8. Phelps DL, Brown DR, Tung B, et al. 28-day survival rates of 6676 neonates with birth weights of 1250 grams or less. Pediatrics 1991;87:7-17
  9. Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004;102:233-48
  10. Patz A. Clinical and experimental studies on retinal neovascularization. XXXIX Edward Jackson Memorial Lecture. Am J Ophthalmol 1982;94:715-43
  11. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001;98:5804-8
  12. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538-44
  13. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133-40
  14. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-3
  15. International Committee for the Classification of Ret